Reactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8+ T cell response and better prognosis in HBV-related hepatocellular carcinoma

Experimental Cell Research

Volumn 358, Issue 2, 2017, Pages 352-359

  Rong, Yihui ^a   Dong, Zheng ^a   Hong, Zhixian ^a   Jin, Yun ^b   Zhang, Wei ^a   Zhang, Bailong ^a   Mao, Wei ^a   Kong, Huifang ^a   Wang, Chunping ^a   Yang, Bin ^a   Gao, Xudong ^a   Song, Zhenyu ^c   Green, Susan E ^c   Song, Haihan K ^c   Wang, Hongbo ^a   Lu, Yinying ^a  

^a BEIJING 302 HOSPITAL   (China)

^b First People's Hospital of Yunnan Province   (China)

^c Dicat Biomedical Computation Centre   (Canada)

Author keywords

CD8+ T cell; HBV related hepatocellular carcinoma; Microbiome

Indexed keywords

TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR;

ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL IMMUNITY; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM LONGUM; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COMMENSAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS HIRAE; ESCHERICHIA COLI; HEPATITIS B; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; BIFIDOBACTERIALES INFECTION; GRAM POSITIVE INFECTION; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; VIROLOGY;

BIFIDOBACTERIALES INFECTIONS; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; ENTEROCOCCUS HIRAE; FORKHEAD TRANSCRIPTION FACTORS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 85023596392     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2017.07.009     Document Type: Article

References (21)

1. Medler, T.R., Cotechini, T., Coussens, L.M., Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer 1 (2015), 66–75, 10.1016/j.trecan.2015.07.008.
2. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211 (2006), 214–224, 10.1111/j.0105-2896.2006.00391.x.
3. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61, 10.1016/j.immuni.2014.06.010.
4. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med., 5, 2013, 200, 10.1126/scitranslmed.3006504.
5. Jiang, Y., Li, Y., Zhu, B., T-cell exhaustion in the tumor microenvironment. Cell Death Dis., 6, 2015, e1792, 10.1038/cddis.2015.162.
6. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
7. Vetizou, M., Pitt, J.M., Daillere, R., Lepage, P., Waldschmitt, N., Flament, C., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084, 10.1126/science.aad1329 (80-.).
8. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089, 10.1126/science.aac4255 (80-.).
9. Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45 (2016), 931–943, 10.1016/j.immuni.2016.09.009.
10. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342 (2013), 971–976, 10.1126/science.1240537.
11. Bisceglie, A.M. Di, Hepatitis B and hepatocellular carcinoma. Hepatology 49 (2009), S56–S60, 10.1002/hep.22962.
12. Lee, J.G., Kang, C.M., Park, J.S., Kim, K.S., Yoon, D.S., Choi, J.S., et al. The actual five-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med. J. 47 (2006), 105–112, 10.3349/ymj.2006.47.1.105.
13. Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., et al. Cancer and the gut microbiota: an unexpected link. Sci. Transl. Med., 7, 2015, 271, 10.1126/scitranslmed.3010473.
14. Rahman, A.H., Taylor, D.K., Turka, L.A., The contribution of direct TLR signaling to T cell responses. Immunol. Res. 45 (2009), 25–36, 10.1007/s12026-009-8113-x.
15. Wang, E.C.Y., McSharry, B., Retiere, C., Tomasec, P., Williams, S., Borysiewicz, L.K., et al. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 99 (2002), 7570–7575, 10.1073/pnas.112680099.
16. De Felice, M., Turco, M.C., Costanzo, F., Corbo, L., Ferrone, S., Venuta, S., Inhibition by anti-HLA class I mAb of IL-2 and IL-2 receptor synthesis in lymphocytes stimulated with PHA-P. Cell. Immunol. 126 (1990), 420–427 http://www.ncbi.nlm.nih.gov/pubmed/2311126 (Accessed 1 March 2017).
17. Chen, G., Lin, W., Shen, F., Iloeje, U.H., London, W.T., Evans, A.A., Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 101 (2006), 1797–1803, 10.1111/j.1572-0241.2006.00647.x.
18. Duraiswamy, J., Kaluza, K.M., Freeman, G.J., Coukos, G., Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res., 73, 2013, 10.1158/0008-5472.CAN-12-4100.
19. Schwabe, R.F., Jobin, C., The microbiome and cancer. Nat. Rev. Cancer 13 (2013), 800–812, 10.1038/nrc3610.
20. Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4. Cancer Cell. 21 (2012), 504–516, 10.1016/j.ccr.2012.02.007.
21. Beck, K.E., Blansfield, J.A., Tran, K.Q., Feldman, A.L., Hughes, M.S., Royal, R.E., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24 (2006), 2283–2289, 10.1200/JCO.2005.04.5716.